Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 16:02 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment...
March 05, 2026 16:21 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia...
March 03, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune...
February 24, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval...
February 03, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune...
January 12, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient...
January 05, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...
December 17, 2025 09:24 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for...
December 15, 2025 16:01 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for...
December 15, 2025 06:30 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 ...